ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "fibromyalgia"

  • Abstract Number: 2233 • ACR Convergence 2022

    Machine Learning Uncovers Novel mRNAs Expressed in Fibromyalgia

    Lena Kolb1, Mark Rudolph1, Alan Kivitz2, Scott Rey1, Roberta Alexander1, Anja Kammesheidt3 and Geoffrey Stephens1, 1Exagen, Inc., Vista, CA, 2Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, 3self, Laguna Beach, CA

    Background/Purpose: Fibromyalgia is a debilitating pain condition that affects roughly 12 million people in the United States. Although preliminary diagnostic criteria have been established by…
  • Abstract Number: 0733 • ACR Convergence 2022

    Median Patient Global Assessment Varies Far More According to FAST4 (fibromyalgia Assessment Screening Tool) and MDS2 (MDHAQ Depression Screen) on a Single MDHAQ (multidimensional Health Assessment Questionnaire) Than According to Primary Diagnosis

    Theodore Pincus1, Kathryn Gibson2, Juan Schmukler1, Tengfei Li3 and Joel Block1, 1Rush University Medical Center, Chicago, IL, 2Liverpool Hospital, Sydney, Australia, 3Georgetown University, Washington, DC

    Background/Purpose: Patient global assessment (PATGL) is a component of DAS28 (disease activity score 28) and CDAI (clinical disease activity index) to assess patients with rheumatoid…
  • Abstract Number: 2235 • ACR Convergence 2022

    Clinical Impact of a Digital Behavioral Therapy for Fibromyalgia Management in a Decentralized Trial

    Yifei Dai1, Michael Rosenbluth2, Michael Gendreau3, Nicolette Vega4, Zunera Ghalib4, Allison Kraus4 and Brian Keefe5, 1Swing Therapeutics, Gainesville, FL, 2Swing Therapeutics, San Francisco, CA, 3GENDREAU CONSULTING, LLC, Poway, CA, 4Swing Therapeutics, San Francisco, 5Swing Therapeutics, New York, NY

    Background/Purpose: Cognitive behavioral therapy (CBT) has demonstrated level 1A evidence for management of fibromyalgia (FM). Acceptance and Commitment Therapy (ACT), a form of CBT, has…
  • Abstract Number: 1216 • ACR Convergence 2022

    Subclinical Vascular Disease Is More Prevalent in above-30 Adult Fibromyalgia: A Preliminary Report of a Hospital-based Cross-sectional Study from South India

    Salil Ganu, C. B. Mithun and Jyothi Visalakshy, Amrita Institute of Medical Sciences, Kochi, India

    Background/Purpose: Fibromyalgia is known to be associated with cardiovascular events and mortality. We aimed to compare the prevalence of subclinical atherosclerosis (SAT), a surrogate marker…
  • Abstract Number: 2236 • ACR Convergence 2022

    Association of microRNA-30b Plasma Expression with Fibromyalgia Clinical Features and with Corneal Small Nerve Fiber Pathology

    Laura Aline Martínez Martínez1, Fausto Sánchez Muñoz1, Manuel Ramírez Fernández2, Yaneli Juárez Vicuña1, Mario Peña-Peña1, Carlos Alfonso Guzman Martin1, Itzel Palafox Sosa1 and Manuel Martínez-Lavín1, 1Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico, 2APEC Hospital de la ceguera, Ciudad de México, Mexico

    Background/Purpose: There is a clear association between fibromyalgia and small fiber neuropathy. Dorsal root ganglia contain the small nerve fiber nuclei. Severe fibromyalgia is associated…
  • Abstract Number: 1218 • ACR Convergence 2022

    Prevalence and Impact of Widespread Pain and Fibromyalgia on Measurement of Disease Severity in Psoriatic Arthritis: Lessons from the CorEvitas Registry

    Philip J Mease1, Alexis Ogdie2, Dimitrios Pappas3, George Reed4 and Joel Kremer5, 1Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 2Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 3CorEvitas, LLC, Waltham, MA, 4The Corrona Research Foundation and University of Massachusetts, Albany, NY, 5The Corrona Research Foundation, Delray Beach, FL

    Background/Purpose: Fibromyalgia (FM) occurs concomitantly with inflammatory rheumatic disease, including psoriatic arthritis (PsA), in up to 20% of patients and chronic widespread pain (CWP) in…
  • Abstract Number: 2256 • ACR Convergence 2022

    Increased Brain Functional Connectivity to the Insula Is Associated with Nociplastic Pain in Psoriatic Arthritis

    Flavia Sunzini1, Kristian Stefanov1, Salim Al-Wasity1, Steven E Harte2, Richard E Harris2, Daniel J Clauw2, Stefan Siebert3, Carl Goodyear1, Gordon Waiter4 and Neil Basu1, 1University of Glasgow, Glasgow, Scotland, United Kingdom, 2University of Michigan, Ann Arbor, MI, 3Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Scotland, United Kingdom, 4University of Aberdeen, Aberdeen, Scotland, United Kingdom

    Background/Purpose: Pain is a hallmark feature of psoriatic arthritis (PsA); however, its apparent multi-factorial nature makes it difficult for rheumatologists to assess and manage. Clinically,…
  • Abstract Number: 1219 • ACR Convergence 2022

    Gender-Related Clinical Profile of Fibromyalgia Patients

    Mark Berman1, Liane banon2, Omer Shlezinger3, Laurence Mangel4, Jacob Ablin1 and Valerie Aloush5, 1Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 2Department of Gastroenterology and Hepatolgy, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 3Internal Medicine F, Tel Aviv, Israel, 4Sackler faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 5Tel Aviv Medical Center, Tel Aviv, Israel

    Background/Purpose: Fibromyalgia is a chronic pain disorder characterized by widespread pain, fatigue, sleep disturbances, cognitive dysfunction and frequent psychiatric comorbidities. Estimated prevalence of fibromyalgia is…
  • Abstract Number: 1220 • ACR Convergence 2022

    Autonomic Dysfunction in Sjogren’s Disease

    Ardy Fenando1, Jordan Estes1, Maha Mohamad1, Sareena Shah2, John Lee2, Duaa Jabari1, Joshua Baker3 and Ghaith Noaiseh1, 1University of Kansas Medical Center, Kansas City, KS, 2University of Missouri-Kansas City, Kansas City, MO, 3University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Sjogren's Disease (SjD) is a heterogenous autoimmune disease associated with debilitating symptoms. Autonomic dysfunction (AD) is common in SjD and may contribute to symptom…
  • Abstract Number: 0127 • ACR Convergence 2021

    Interleukin 1 Receptor Antagonist (IL-1Ra) Variable Number of Tandem Repeat (VNTR) Polymorphism in Fibromyalgia Patients in South India

    Arun Tiwari1, Mithun CB2, Lalitha Biswas3, Sandeep Surendran3, Vishal Marwaha3, Pranav Chickermane3 and Amisha Shahul3, 1Amrita Institute of Medical Sciences, Ernakulam, India, 2Amrita Institute of Medical Sciences, Muvattupuzha, India, 3Amrita Institute of Medical Sciences, Kochi, India

    Background/Purpose: Interleukin-1 receptor antagonist (IL-1Ra) variable number of tandem repeats (VNTR) polymorphism is a known to influence the production of IL-1Ra and has been considered…
  • Abstract Number: 0474 • ACR Convergence 2021

    Correlation of Fibromyalgia Survey Questionnaire and Quantitative Sensory Testing Among Patients with Active Rheumatoid Arthritis

    Meriah Moore1, Beth Wallace2, Jing Song3, Lutfiyya Muhammad4, Andrew Heisler5, Daniel Clauw1, Marcy Bolster6, Wendy Marder1, Tuhina Neogi7, Alyssa Wohlfahrt8, Dorothy Dunlop9 and Yvonne Lee9, 1University of Michigan, Ann Arbor, MI, 2Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, 3Northwestern University, Worthington, IL, 4Northwestern University Feinberg School of Medicine, Chicago, IL, 5Bronson Rheumatology Specialists, Kalamazoo, MI, 6Massachusetts General Hospital, Boston, MA, 7Boston University School of Medicine, Boston, MA, 8Tufts University School of Medicine, Boston, MA, 9Northwestern University, Chicago, IL

    Background/Purpose: Patients with rheumatoid arthritis (RA) commonly demonstrate disordered pain processing, termed central sensitization (CS). CS is typically measured using quantitative sensory testing (QST), which…
  • Abstract Number: 0475 • ACR Convergence 2021

    Quantitative Analysis of Gender and Racial Disparities in Randomized Controlled Trials of Fibromyalgia

    Rami Diab1, Ali Malik2, Mahmoud Al Rifai3 and Dennis Ang4, 1Wake Forest Baptist Health/Wake Forest School of Medicine, Winston-Salem, NC, 2Wake Forest Baptist Health / Wake Forest School of Medicine, Winston-Salem, NC, 3Baylor College of Medicine, Houston, TX, 4Wake Forest School of Medicine, Winston-Salem, NC

    Background/Purpose: Fibromyalgia is a chronic pain syndrome characterized by widespread musculoskeletal pain, mood disorders, fatigue, and cognitive and sleep disturbance. Mainstay treatments include tricyclic antidepressants,…
  • Abstract Number: 0476 • ACR Convergence 2021

    Factors Associated with Pain Reduction and Improved Well-Being Among Fibromyalgia Patients Using Medical Cannabis

    Marc Martel1, Lilach Eyal Waldman1, Romina Sotoodeh1, Antonio Vigano1, Yola Moride2, Michelle Canac-Marquis3, Rihab Gamaoun3, Maja Kalaba4, Pierre Beaulieu2, Julie Desroches2, Mark A. Ware4, Jordi Perez3, Yoram Shir3 and Mary-Ann Fitzcharles1, 1McGill University, Montréal, QC, Canada, 2Université de Montréal, Montréal, QC, Canada, 3McGill University Health Centre, Montréal, QC, Canada, 4Canopy Growth Corporation, Montréal, QC, Canada

    Background/Purpose: Fibromyalgia (FM) is characterized by a constellation of symptoms that are often poorly responsive to current treatments, and patients are increasingly turning to medical…
  • Abstract Number: 0477 • ACR Convergence 2021

    TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia in the RELIEF Study: Positive Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy and Safety Trial

    Gregory Sullivan1, Mary Kelley2, Annabelle Iserson1, Perry Peters2, Ashild Peters2, Candace Flint1, Judy Gendreau3, Herb Harris1, Ben Vaughn4 and Seth Lederman5, 1Tonix Pharmaceuticals, Inc., Chatham, NJ, 2Tonix Pharmaceuticals, Inc., San Diego, CA, 3Gendreau Consulting, LLC, Poway, CA, 4Rho, Inc., Cary, NC, 5Tonix Pharmaceuticals, Inc., South Dartmouth, MA

    Background/Purpose: Fibromyalgia (FM) is characterized by chronic widespread pain, fatigue, and nonrestorative sleep, a symptom constellation suggestive of a pathological disturbance in central pain processing…
  • Abstract Number: 0659 • ACR Convergence 2021

    Understanding the Rheumatologic Population We Serve Through Objective Analysis of Referrals and Diagnoses: Does Perception Match Actual Data?

    Kirsten Koons1, Jonida Cote2, Sanjeev Shrestha3, Melissa Band3, David Pugliese4 and Eric Newman3, 1Geisinger Medical Center, Lewisburg, PA, 2Geisinger Medical Center, Orefield, PA, 3Geisinger Medical Center, Danville, PA, 4Geisinger Medical Center, Wilkes Barre, PA

    Background/Purpose: Healthcare access in our Rheumatology Department is challenging. Fibromyalgia is perceived to occupy a large portion of clinic visits, leading to increased wait times…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 23
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology